Ludwig Enterprises Files S-1/A for IPO, Plans Reverse Split & Rebrand

TL;DR

**LUDG is a high-risk bet on an early-stage genomics play, with an uplisting and reverse split that could either unlock value or leave investors holding the bag if the offering fails.**

AI Summary

Ludwig Enterprises, Inc. (LUDG), an early-stage genomics-based diagnostic company, filed an S-1/A on October 14, 2025, for a firm commitment public offering of its Common Stock. The company, which has not yet sold any products, aims to launch its proprietary mRNA genetic testing kits, including the Revealia™ Breast test, by the end of Q4 2025. Key corporate actions approved by shareholders on June 16, 2025, include a reverse stock split between 1-for-50 and 1-for-250, a name change to 'Revealia Diagnostics, Inc.', and ratification of past corporate actions including prior reverse stock splits in 2009, 2011, and 2012. The offering is contingent on FINRA approval for the reverse stock split and subsequent listing on an unnamed exchange, with the current trading on OTCID under 'LUDG'. The company plans to convert 700,000,000 shares of Convertible Preferred Stock into Common Stock and a portion of outstanding convertible notes, representing accrued interest and original issuance discounts, into Common Stock, using offering proceeds to pay remaining note balances. Management changes include the resignation of Dr. Marvin S. Hausman from the Board on June 5, 2025 (remaining CSO), Charles T. Todd Jr. as CEO on July 24, 2025, and the appointment of Jose Antonio Reyes as Interim CEO on October 1, 2025. New independent directors Garth Lees-Rolfe and Corain McGinn were appointed on June 23, 2025, and September 5, 2025, respectively.

Why It Matters

This S-1/A filing signals Ludwig Enterprises' intent to transition from an OTCID-listed entity to a potentially larger exchange, a critical step for an early-stage genomics company seeking significant capital. For investors, the proposed reverse stock split (1-for-50 to 1-for-250) and uplisting are high-risk, high-reward moves aimed at attracting institutional interest, but also carry the risk of failure if FINRA or the target exchange do not approve. Employees and customers of the future 'Revealia Diagnostics, Inc.' will see the company's strategic shift towards commercialization of its mRNA genetic testing kits, particularly the Revealia™ Breast test, by Q4 2025, placing it in direct competition with established diagnostic firms.

Risk Assessment

Risk Level: high — The company explicitly states it is an 'early-stage genomics technology and health related company without any products or services currently available for sale' and 'may not be able to successfully develop or bring products or services to market.' The offering is contingent on a reverse stock split (1-for-50 to 1-for-250) and an uplisting, both of which are subject to regulatory approval (FINRA) and exchange approval, with no guarantee of success. If the listing application is not approved, the offering will be terminated.

Analyst Insight

Investors should approach LUDG with extreme caution, recognizing it as a highly speculative investment in an early-stage company with no current revenue. Monitor the progress of the reverse stock split and uplisting approvals, as failure to secure these will terminate the offering. Consider the significant dilution risk from the conversion of 700,000,000 shares of Convertible Preferred Stock and convertible notes into Common Stock.

Executive Compensation

Key Numbers

• 700,000,000 — shares of Common Stock (total shares Convertible Preferred Stock holders may convert into)
• $0.001 — par value per share (par value of Common Stock)
• 1-for-50 to 1-for-250 — reverse stock split ratio range (approved range for reverse stock split)
• 1.0% — non-accountable expense allowance (payable to underwriters of the offering)
• $1.235 billion — annual gross revenues threshold (threshold for ceasing to be an 'emerging growth company')
• $700 million — market value threshold (threshold for ceasing to be a 'smaller reporting company' or 'large accelerated filer')
• $100 million — annual revenue threshold (threshold for being a 'smaller reporting company')
• $250 million — market value threshold (alternative threshold for being a 'smaller reporting company')
• 30 days — notice period (Charles T. Todd Jr.'s resignation as CEO effective 30 days after notification)
• 45-day — option period (option granted to underwriters for over-allotments)

Key Players & Entities

• LUDWIG ENTERPRISES, INC. (company) — Registrant and issuer of common stock
• Scott J. Silverman (person) — Chief Financial Officer of Ludwig Enterprises, Inc.
• Ross Carmel, Esq. (person) — Legal counsel from Sichenzia Ross Ference Carmel, LLP
• Leslie Marlow, Esq. (person) — Legal counsel from Blank Rome LLP
• Patrick J. Egan, Esq. (person) — Legal counsel from Blank Rome LLP
• Dr. Marvin S. Hausman (person) — Chief Scientific Officer, resigned from Board on June 5, 2025
• Garth Lees-Rolfe (person) — New independent director appointed on June 23, 2025
• Charles T. Todd Jr. (person) — Resigned as Chief Executive Officer on July 24, 2025
• Corain McGinn (person) — New independent director appointed on September 5, 2025
• Jose Antonio Reyes (person) — Appointed Interim CEO on October 1, 2025

FAQ

Risk Factors

• Lack of Operating History and Product Sales [high — financial]: The company has not yet sold any products and is in the early stages of development. The launch of its proprietary mRNA genetic testing kits, including the Revealia™ Breast test, is planned for the end of Q4 2025. This lack of revenue generation poses a significant risk to future financial performance.
• Dependence on FINRA Approval for Listing [high — regulatory]: The firm commitment public offering is contingent on FINRA approval for the reverse stock split and subsequent listing on an unnamed exchange. Delays or denial of FINRA approval could prevent the offering from proceeding as planned.
• Execution Risk of Product Launch [high — operational]: The success of the company hinges on the timely and effective launch of its mRNA genetic testing kits. Any delays or issues in product development, manufacturing, or market adoption could severely impact revenue and growth prospects.
• Significant Shareholder Dilution from Conversions [medium — financial]: The company plans to convert 700,000,000 shares of Convertible Preferred Stock and a portion of outstanding convertible notes into Common Stock. This conversion, especially if occurring before significant revenue generation, could substantially dilute existing shareholders.
• Evolving Genomics Diagnostic Landscape [medium — regulatory]: The genomics-based diagnostics market is rapidly evolving with new technologies and competitors emerging. Ludwig Enterprises faces the risk of being outpaced by advancements or facing intense competition from established players.
• Reliance on Future Financing [medium — financial]: As an early-stage company with no product sales, Ludwig Enterprises will likely require significant future financing to fund operations, product development, and market expansion. The ability to secure such financing on favorable terms is not guaranteed.
• Management Transition and Board Changes [low — operational]: The company has experienced recent management changes, including the resignation of its CEO and appointment of an interim CEO, along with new independent director appointments. Such transitions can create short-term instability and impact strategic execution.

Industry Context

Ludwig Enterprises operates in the rapidly advancing genomics-based diagnostics sector. This industry is characterized by significant innovation, high R&D costs, and increasing competition from both established players and emerging biotech firms. The market is driven by the growing demand for personalized medicine and early disease detection, with mRNA technology showing promise for novel diagnostic applications.

Regulatory Implications

The company faces substantial regulatory hurdles, including the need for FINRA approval for its reverse stock split and exchange listing. Furthermore, as a diagnostics company, its products will be subject to stringent FDA regulations and other healthcare compliance requirements, which can be costly and time-consuming to navigate.

What Investors Should Do

1. Monitor FINRA approval status closely.
2. Evaluate the product launch success and market adoption.
3. Assess the impact of share conversions on dilution.
4. Scrutinize management's execution capabilities post-transition.

Key Dates

• 2025-06-16: Shareholder approval of reverse stock split, name change, and ratification of past actions. — Sets the stage for corporate restructuring and potential relisting, impacting share structure and identity.
• 2025-10-14: Filing of S-1/A for public offering. — Initiates the process for raising capital through an IPO, subject to regulatory approvals.
• 2025-Q4: Planned launch of proprietary mRNA genetic testing kits. — Marks the company's entry into revenue-generating activities, critical for future growth.

Glossary

S-1/A

An amended registration statement filed with the SEC for a public offering of securities, providing updated or corrected information. (This is the primary document detailing the company's business, financials, risks, and offering terms for potential investors.)

Firm Commitment Public Offering

An underwriting arrangement where the investment bank buys the securities from the issuer and resells them to the public, assuming the risk of unsold shares. (Indicates the underwriter is confident in the offering and will purchase all shares, providing certainty of capital for the company.)

Reverse Stock Split

A corporate action where a company reduces the number of outstanding shares by consolidating them, typically to increase the per-share price. (Ludwig Enterprises is implementing a significant reverse split (1-for-50 to 1-for-250) to meet exchange listing requirements and potentially improve its stock's market perception.)

mRNA Genetic Testing Kits

Diagnostic tools that utilize messenger RNA (mRNA) to detect genetic information or predispositions, such as for diseases like breast cancer. (These are the company's core products, representing its primary revenue stream and technological focus.)

Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of common stock shares. (A large number of these shares (700,000,000) are slated for conversion into common stock, which will impact the company's capital structure and potentially dilute existing shareholders.)

Convertible Notes

Debt instruments that can be converted into a specified number of common stock shares. (Outstanding convertible notes, including accrued interest and discounts, are also being converted into common stock, further affecting the equity structure.)

Emerging Growth Company (EGC)

A designation under the JOBS Act for companies with less than $1.235 billion in annual gross revenues, allowing for scaled disclosure requirements. (Ludwig Enterprises likely qualifies as an EGC, benefiting from reduced reporting obligations during its early growth phase.)

FINRA

Financial Industry Regulatory Authority, a self-regulatory organization overseeing broker-dealers in the United States. (FINRA approval is a critical gating item for the company's reverse stock split and subsequent listing on a national exchange.)

Year-Over-Year Comparison

This S-1/A filing represents a significant transition from previous filings, as Ludwig Enterprises is now actively pursuing a public offering and preparing for product launch, unlike its earlier stages. Key changes include the proposed reverse stock split to meet listing requirements and a name change to 'Revealia Diagnostics, Inc.', signaling a shift towards commercialization. The filing also details substantial planned conversions of preferred stock and convertible notes, which will alter the capital structure significantly compared to prior periods where such conversions were not imminent.

Key Financial Figures

• $0.001 — r "us"), of shares of its Common Stock, $0.001 par value per share (the "Common Stock"
• $700 million — ock held by non-affiliates is less than $700 million and our annual revenue is less than $10
• $100 million — ion and our annual revenue is less than $100 million during the most recently completed fisc
• $250 million — ock held by non-affiliates is less than $250 million as of the last business day of our seco
• $1.235 b — which our annual gross revenues exceed $1.235 billion, (iii) the last day of our fiscal
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the prece

Filing Documents

• ea0260879-s1a1_ludwig.htm (S-1/A) — 2997KB
• ea026087901ex23-1_ludwig.htm (EX-23.1) — 3KB
• image_001.jpg (GRAPHIC) — 5KB
• image_002.jpg (GRAPHIC) — 21KB
• image_003.jpg (GRAPHIC) — 27KB
• image_004.jpg (GRAPHIC) — 18KB
• image_005.jpg (GRAPHIC) — 11KB
• image_006.jpg (GRAPHIC) — 22KB
• image_007.jpg (GRAPHIC) — 29KB
• fin_001.jpg (GRAPHIC) — 6KB
• fin_002.jpg (GRAPHIC) — 2KB
• 0001213900-25-098238.txt ( ) — 11418KB
• ludg-20250630.xsd (EX-101.SCH) — 79KB
• ludg-20250630_cal.xml (EX-101.CAL) — 49KB
• ludg-20250630_def.xml (EX-101.DEF) — 409KB
• ludg-20250630_lab.xml (EX-101.LAB) — 677KB
• ludg-20250630_pre.xml (EX-101.PRE) — 435KB
• ea0260879-s1a1_ludwig_htm.xml (XML) — 1608KB

Underwriting

Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the underwriters. We refer you to "Underwriting" beginning on page 86 for additional information regarding underwriters' compensation. We have granted a 45-day option to the representative of the underwriters to purchase up to additional shares of Common Stock solely to cover over-allotments, if any. ThinkEquity The date of this prospectus is , 2025 TABLE OF CONTENTS Page Prospectus Summary 1 The Offering 5 Summary Consolidated Financial Information 7 Risk Factors 9 Use of Proceeds 34 Determination of Offering Price 35 Capitalization 36 Dividend Policy 37 Market for Common Equity and Related Stockholder Matters 37 Forward-Looking 37

Dilution

Dilution 38 Management's Discussion and Analysis of Financial Condition and Results of Operations 40

Business

Business 54 Management 66 Executive Compensation 72 Security 77 Certain Relationships and Related Transactions 79 Description of Securities 83 Shares Eligible for Future Sale 85

Underwriting

Underwriting 86 Transfer Agent and Registrar 95 Legal Matters 95 Experts 95 Disclosure of Commission's Position on Indemnification for Securities Act Liabilities 96 Nevada Anti-takeover Law 96 Where You Can Find Additional Information 97 Index to Financial Statements F-1 i About this Prospectus You should rely only on the information contained in this prospectus and in any free writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, shares of our Common Stock only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our Common Stock. We have not done anything that would permit this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and to observe any restrictions as to this Offering and the distribution of this prospectus applicable to that jurisdiction. Market and Industry Data Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets which we believe to be reasonable. Although we believe the data from these third-party sources is reliable, we have not

View Full Filing

View this S-1/A filing on SEC EDGAR